The European Medicines Agency (EMA) last week added an autoimmune condition known as Guillain-Barré syndrome (GBS) as a possible side effect to the product information on AstraZeneca/Oxford University's Vaxzevria (or "AZD1222") experimental adenovirus vectored vaccine. GBS is a neurological...